Synribo Clears FDA Hurdle, Gains Nod in CML Patients

Three years after a new drug application was first submitted for leukemia drug omacetaxine mepesuccinate, during which the product moved twice into different hands via M&A transactions, the FDA granted a long-awaited nod Friday.

To continue reading subscribe now to BioWorld Asia (formerly International)